EPOC B Trial

Trial Name

EPOC B - An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases.

Description

Multicentre randomised control trial of peri-operative versus post-operative chemotherapy for patients who have colorectal cancer liver metastases.

Objectives

Primary Objective

• To determine whether it is feasible to recruit to a trial of peri-operative versus post-operative chemotherapy.

Secondary Ojectives

• To determine:
  • The completion rate of planned chemotherapy cycles in the peri-operative and post operative arms;
  • The surgical mortality and complication rates;
  • Treatment related toxicity;
  • The effects of treatment on QoL;
  • The overall survival for each treatment arm

Design

Multicentre randomised control trial for patients who have colorectal cancer with resectable liver metastases. Eligible patients will be randomised to receive either 24 weeks of chemotherapy treatment post-operatively (Arm A) or 12 weeks of chemotherapy treatment pre-operatively and 12 weeks post-operatively (Arm B).

Status

Complete

Population

78 colorectal cancer patients with liver metastases deemed resectable in whom the oncologist feels chemotherapy would be beneficial and who are fit for combination chemotherapy.

Contact details

All Trial enquiries should be addressed to [email protected]